LENZ Company Profile and Key Details

LENZ has shown mixed momentum, gaining 24.47% over the past week and -49.35% over the past quarter, though year-to-date performance is up 21.12%. Short-term trend indicators are bullishly aligned (SMA20 -2.09%, SMA50 -15.53%, SMA200 -53.47%). The stock’s 14-day RSI is 41.91 (neutral), while the ATR of 1.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -73.17% below its high and over 17.77% above its low. Average 10-day trading volume of 848.73 thousand shares is in line with the 3-month average of 864.06 thousand, indicating normal recent market interest.

LENZ Therapeutics, Inc. has 28.52 million shares outstanding. The public float is 13.13 million shares, elevated short interest at 24.82% of float. This equals 3.82 million shares. The short ratio is 14.15 days. Institutional investors hold 112.76% of the float. Insiders own 2.65%. Versant Venture Capital VI, L.P. holds 764.13 thousand shares, RA CAPITAL MANAGEMENT, L.P. has 694.76 thousand shares and Schimmelpennink Evert B. has 77.29 thousand shares.

LENZ Therapeutics, Inc. generated EPS of -$2.11 over the past year. Five-year average earnings growth is -181.63%. Wall Street analysts project EPS growth of 30.84% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 6 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $67.00 to $12.00. The high target offers 1609.18% upside. The low target suggests 206.12% downside. The mean target is $36.44. This offers 829.59% upside. LENZ Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 11, 2026, missed forecasts by -2.86%. The prior quarter beat by 20.0%. Over the last six quarters, Apple has recorded several small beats. These include -3.64% in May 07, 2025.

LENZ Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.05. This means the shares are trading above this model’s fair value.

LENZ Therapeutics, Inc. (NASDAQ:LENZ) closed at $3.92 USD, gaining $0.19 (5.24%) from the previous close of $3.72. The stock is currently mid-range between its 52-week high and low $3.60 and $50.40. With a market capitalization of about $122.75 million, LENZ Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.63). Key stats such as the average daily volume over the past year has been around 859.53 thousand shares, in line with its 52-week average. Headquartered in Solana Beach, CA, LENZ Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Evert Schimmelpennink, the company employs approximately 152 people and listed since June 25, 2021. LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States.

LENZ Therapeutics, Inc. trades at a P/E ratio of -0.96, slightly below the S&P 500 average, with a price-to-sales ratio of 5.72 and a price-to-book ratio of 0.56 suggesting the stock is closer to book value. The P/FCF stands at -1.07, also above market averages.

LENZ Therapeutics, Inc. (NASDAQ:LENZ) shares are up 21.12% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows LENZ Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.96. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $40.47, suggesting 932.4% upside. Our AI forecast model points to short-term weakness (-7.91% over two weeks), a medium-term fall (-85.46% over three months), and a longer-term loss (-94.39% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that LENZ Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -7.91%, with price expected at $3.61 by October 09, 2026, within a range of $2.99 to $4.15 3-Month Outlook: Projected fall of -85.46%, reaching $0.57 by December 24, 2026, with a range of $0.00 to $1.16. 1-Year Outlook: Projected loss of -94.39%, with price at $0.22 by September 24, 2027, within a range of $0.00 to $0.00.